HomeCompareSAEF vs MRK

SAEF vs MRK: Dividend Comparison 2026

SAEF yields 0.38% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $10.5K in total portfolio value
10 years
SAEF
SAEF
● Live price
0.38%
Share price
$27.04
Annual div
$0.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$39.16
Full SAEF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SAEF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSAEFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SAEF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SAEF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SAEF
Annual income on $10K today (after 15% tax)
$32.47/yr
After 10yr DRIP, annual income (after tax)
$33.29/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $774.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SAEF + MRK for your $10,000?

SAEF: 50%MRK: 50%
100% MRK50/50100% SAEF
Portfolio after 10yr
$25.5K
Annual income
$494.73/yr
Blended yield
1.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SAEF
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SAEF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSAEFMRK
Forward yield0.38%3.25%
Annual dividend / share$0.10$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$20.2K$30.7K
Annual income after 10y$39.16$950.29
Total dividends collected$387.00$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SAEF vs MRK ($10,000, DRIP)

YearSAEF PortfolioSAEF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,738$38.20$11,192$351.54$454.00MRK
2$11,528$38.34$12,524$392.70$996.00MRK
3$12,374$38.47$14,015$438.65$1.6KMRK
4$13,278$38.59$15,682$489.96$2.4KMRK
5$14,247$38.70$17,547$547.23$3.3KMRK
6$15,283$38.80$19,632$611.16$4.3KMRK
7$16,391$38.90$21,963$682.53$5.6KMRK
8$17,578$39.00$24,571$762.18$7.0KMRK
9$18,847$39.08$27,486$851.08$8.6KMRK
10$20,206$39.16$30,745$950.29$10.5KMRK

SAEF vs MRK: Complete Analysis 2026

SAEFStock

The fund seeks long-term capital appreciation.

Full SAEF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SAEF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SAEF vs SCHDSAEF vs JEPISAEF vs OSAEF vs KOSAEF vs MAINSAEF vs JNJSAEF vs ABBVSAEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.